NCT02801786

Brief Summary

This is a double-blind placebo-controlled randomized clinical trial to test the use of tamoxifen or lidocaine for diminishing the pain and discomfort while performing mammography, intending to include 450 patients distributed between the three groups.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
450

participants targeted

Target at P75+ for phase_2 pain

Timeline
Completed

Started Nov 2018

Typical duration for phase_2 pain

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 13, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 16, 2016

Completed
2.4 years until next milestone

Study Start

First participant enrolled

November 1, 2018

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2020

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

May 4, 2018

Status Verified

May 1, 2018

Enrollment Period

2 years

First QC Date

June 13, 2016

Last Update Submit

May 1, 2018

Conditions

Keywords

MammographyPremedicationPainDiscomfortBreast

Outcome Measures

Primary Outcomes (1)

  • Tamoxifen for pain during mammography

    An additional 15% of patients who did not experience pain during mammography using the medication.

    Between review, test, randomization, application of results, data analysis and delivery of results for publication will be 24 months.

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Five capsules containing placebo

Drug: Placebo

Tamoxifen

EXPERIMENTAL

Five capsules containing 20mg of tamoxifen.

Drug: PlaceboDrug: Tamoxifen

Lidocaine

EXPERIMENTAL

One sachet containing lidocaine gel at 4%

Drug: PlaceboDrug: Lidocaine

Interventions

The arm will be composed of 03 women who used placebo capsules and gel.

Also known as: Starch
LidocainePlaceboTamoxifen

The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.

Lidocaine

The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.

Tamoxifen

Eligibility Criteria

Age40 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with mastalgia in the mastology program with age 40 who have indication for mammography.

You may not qualify if:

  • Patients who do not wish to participate in the study
  • Patients who underwent prosthetic silicone implants
  • Patients who mammoplasty (breast reduction or mastopexy) were submitted
  • Pregnant women
  • Patients allergic to tamoxifen or to lidocaine, heart disease, or patients with a history deep vein thrombosis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidade Federal de Goias

Goiânia, Goiás, 74605050, Brazil

Location

Related Publications (1)

  • Kashikar-Zuck S, Keefe FJ, Kornguth P, Beaupre P, Holzberg A, Delong D. Pain coping and the pain experience during mammography: a preliminary study. Pain. 1997 Nov;73(2):165-172. doi: 10.1016/S0304-3959(97)00114-0.

MeSH Terms

Conditions

Pain

Interventions

StarchLidocaineTamoxifen

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

GlucansBiopolymersPolymersMacromolecular SubstancesDietary CarbohydratesCarbohydratesPolysaccharidesAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesStilbenesBenzylidene CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Responsible Party was entered in the old format as Ruffo Freitas-Junior,Federal University of Goias.

Study Record Dates

First Submitted

June 13, 2016

First Posted

June 16, 2016

Study Start

November 1, 2018

Primary Completion

November 1, 2020

Study Completion

June 1, 2021

Last Updated

May 4, 2018

Record last verified: 2018-05

Locations